Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M

  • Home Blog The business cocktail bayers biologics

Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M

May 16, 2019

Ginkgo announces to buy Warp Drive Bio’s genome mining platform

Ginkgo Bioworks has announced to acquire the genome mining platform from Warp Drive Bio, a subsidiary of REVOLUTION Medicines.  The acquisition will give Gingko access to Warp Drive Bio’s genome mining team, technology, and database. This collaboration will help merge biological information and advance its applications in other pharmaceutical industry. The Genome mining platform will augment Ginkgo’s sequencing capabilities, biological codebase, bioinformatics and machine learning tools for gene discovery.

Vertex, Kymera collaborates to develop Protein Degradation Medicine  

Vertex Pharmaceuticals– best known for its Cystic Fibrosis clinical development- is going to form an alliance with Kymera Therapeutics to accelerate the therapeutic market of different diseases, beyond Cystic Fibrosis. Vertex will pay Kymera USD 70 million upfront. Vertex so far has been focusing on developing drugs for rare genetic diseases caused due to mutations. And this deal will pave the way for Vertex to enter into the world of Protein degradation.

ArcherDX nets USD 60 M to advance Minimum Residual Disease diagnostics

ArcherDX successfully has raised USD 60 million to advance in the clinical development of minimum residual disease giving the company an opportunity to ingress into a market worth more than USD 20 million. Furthermore, the funds will accelerate the clinical development of its companion diagnostic program spanning solid and blood tumours, as well as circulating tumour DNA tests.

Bayer to invest USD 150 M for building a new therapy facility

Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be built on Bayer’s campus in Berkeley, California, will focus primarily on biologic therapies for oncology, cardiology and additional speciality care areas. The new facility will leverage automation, digital capabilities and single-use bioprocessing technologies to allow faster production of medicines.

Downloads

Article in PDF

Recent Articles
medtech-news-for-zimmer-biomet-orthocell-hologic
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Dec 05, 2024

FDA Approves Zimmer Biomet’s Oxford® Cementless Partial Knee; ReCerf® Sets Milestone as First All-Ceramic Hip Resurfacing Approved Worldwide; Orthocell Achieves US FDA 510(k) Clearance Milestone for Remplir Regulatory Study; Hologic’s Research Shows AI Breast Imaging Maintains Performance Across All Demographics; GE HealthCare Expands MRI Capabilities with Sonic DL’s Advanced Deep Learning; Terumo Unveils the R2P NaviCross Peripheral Support Catheter

applications-of-biochips-in-healthcare
Articles

Dec 04, 2024

Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry

pharma-news-for-applied-therapeutics-alnylam-rigel
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Dec 03, 2024

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

Acute lymphocytic leukemia
Acute Myeloid Leukemia
Atrial Fibrillation
DelveInsight
FDA
Latest pharma news
Myelodysplastic Syndrome Market
news
pharma news
recent pharma news
transthyretin amyloidosis
loader